Dublin, Ireland, 21 September, 2020 – Ovoca Bio, a biopharmaceutical company with a focus on women’s health, is pleased to announce its interim financial statements and report covering the six-months ending 30 June 2020.
Ovoca Bio, a biopharmaceutical company focused on identifying and developing novel therapeutics targeting the large unmet needs in the treatment of female sexual dysfunction, is pleased to announce its interim financial statements and report covering the six-months ending 30 June 2019.
Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Nikolay Myasoyedov, a Non-Executive Director of the Company, has notified the board of his intention to step down from the board of Ovoca with immediate effect for personal reasons.
Ovoca Bio plc (LSE: OVB; ISE: OVXA) will hold its Annual General Meeting (“AGM”) at 12.00 p.m. today at Buswells Hotel, 23-25 Molesworth Steet, Dublin, Ireland. At the AGM, Kirill Golovanov, Chief Executive of Ovoca, will make the following statement:
Ovoca is pleased to announce the publication of its Annual Report and Financial Statements for the year ended 31 December 2018.
Ovoca Bio plc (LSE: OVB; ISE: OVXA) is pleased to announce that its subsidiary IVIX LLC has commenced the process of preparing an integrated Clinical Development Plan for its investigational drug candidate, Libicore (BP-101), for both the US and EU regions with Biorasi LLC, an experienced US-based contract research organization.
Ovoca Bio plc (LSE: OVB) is pleased to provide an operating update relating to its subsidiary, IVIX LLC (IVIX), and confirmation of the acquisition of an additional interest in IVIX that increases Ovoca’s overall holding in IVIX to 59.9 per cent.